By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intellia Therapeutics 

130 Brookline Street, Suite 201

Cambridge  Massachusetts  02139  U.S.A.
Phone: 857-285-6200 Fax: n/a



Company News
Intellia Announces Patent For CRISPR/Cas Genome Editing In China 6/19/2017 11:02:19 AM
Intellia And San Raffaele University And Research Hospital To Combine CRISPR/Cas9 Genome Editing With Enhanced Cell Therapies To Fight Cancer 6/6/2017 8:31:25 AM
CRISPR (CRSP), Editas Medicine (EDIT) and Intellia Fall as Scientific Paper Warns of Unintended Mutations Linked to Gene-Editing 5/31/2017 6:07:53 AM
Intellia Announces Progress With CRISPR/Cas9 At The American Society Of Gene & Cell Therapy Annual Meeting 5/15/2017 10:33:40 AM
Intellia Announces First Quarter 2017 Financial Results 5/2/2017 10:38:08 AM
Intellia And CRISPR (CRSP) Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes 4/26/2017 10:32:20 AM
Patent Fight Continues as CRISPR (CRSP), Intellia, Caribou Biosciences and ERS Genomics Appeal CRISPR Decision 4/13/2017 8:19:07 AM
Intellia Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology Patent 4/11/2017 9:29:40 AM
Intellia’s CEO Has Cambridge-Based Company Moving Forward on Positive in vivo Data 3/20/2017 6:38:02 AM
CRISPR (CRSP), Intellia, Caribou Biosciences And ERS Genomics Provide Update On CRISPR/Cas9 U.S. Patent Interference Proceedings And Grants Of Corresponding Patents In The U.K. 2/16/2017 7:06:22 AM